RetinalGenix Technologies Inc.

GlucoVista is a medical device company focused on developing continuous non-invasive blood glucose monitoring solutions. The company maintains operations and headquarters in Tel Aviv-Yafo, Israel.

SmartlensHealthcareUnited States

67% match

Smartlens, Inc. is a medical device company developing smart contact lenses for continuous 24-hour intraocular pressure monitoring, AI-powered eye imaging, and micro-dose drug delivery. Headquartered in California, the firm aims to transform glaucoma and anterior segment eye disease management.

OptosMedical TechnologyUnited Kingdom

66% match

Optos plc is a company headquartered in Dunfermline, Scotland, United Kingdom. It specializes in ultra-widefield (UWF™) retinal imaging devices for eyecare, providing products that offer a complete view of the retina to aid in the early detection of systemic and ocular diseases.

Kubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.

AIRDOC-B02251 · HealthtechBeijing, China

63% matchPublic

Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.

MediwhaleHealthtechSouth Korea

63% match

Mediwhale is a Korean medical AI company headquartered in Seoul, South Korea. It develops AI medical devices that analyze retinal images to predict cardiovascular, kidney, and eye disease risks early. The company aims to provide a new paradigm for cardometabolic disease prevention.